JoyBridge Kids Acquires Pediatric Advanced Therapy
JoyBridge, a portfolio company of private equity firm Frontline Healthcare Partners, announced on November 4 that it acquired Pediatric Advanced Therapy (PAT). PAT is a pediatric rehabilitation and behavioral health practice with 11 locations in North Carolina. It provides occupational therapy, speech therapy, general counseling, physical therapy and Applied Behavior Analysis services. JoyBridge is a clinic-based applied behavior analysis therapy provider with supplemental services in speech and occupational therapy. The company is based in Mt. Juliet, Tennessee. The move expands the reach and impact of JoyBridge Kids, adding assets that bring a holistic,... Read More »
Align Capital Partners-Backed Premier Biotech Acquires National Test Systems
On November 5, Premier Biotech announced that it acquired National Test Systems (NTS) for an undisclosed price. NTS is a leading provider of rapid point-of-care diagnostic drug screening supplies and services throughout the United States. NTS serves more than 1,500 facilities and is based in Boca Raton, Florida. Premier Biotech delivers rapid and innovative diagnostic solutions that promote health, safety and compliance. The company is a leading provider of proprietary oral fluid (OralTox® and OT-Scan®) and other products, services and technology solutions designed to simplify and provide a seamless end-to-end experience for customers. Premier Biotech’s integrated offering is... Read More »
DoseMe Buys Clinical Decision Support Platform Firstline
DoseMe, a portfolio company of private equity firm Fairlong Capital, announced on November 3 its acquisition of Vancouver, Canada-based Firstline. Firstline is a mobile-first clinical decision support platform. It enables clinicians to rapidly access local, evidence-based infectious disease treatment guidance, susceptibility patterns and antimicrobial stewardship resources. Headquartered in Jupiter, Florida, DoseMe is a global leader in model-informed precision dosing software. DoseMe optimizes non-time-critical dosing for antimicrobials, oncology agents, immunosuppressants and more, reducing drug-related risks. The combination of DoseMe and Firstline creates a single, connected experience... Read More »
Asker Acquires Swiss Company Innomedicus
On November 3, medical technology firm Asker Healthcare Group announced that it acquired Swiss company Innomedicus. Innomedicus is a niche distributor specializing in equipment and services for precision diagnostics and minimally invasive procedures in urology. The company is based in Switzerland and employs ten people. According to the original deal press release, Innomedicus reported revenues of approximately SEK 50 million (approximately $5.3 million USD) in 2024. Asker Healthcare Group is a European healthcare company that partners with caregivers and patients across Europe, providing medical products and solutions. The group focuses on improving patient outcomes, reducing the total... Read More »
October Deal Volume Dips 17% as Market Pressures Mount
The last few months have been a relentless storm of reimbursement and market changes. Far from finding calm, October has seen new challenges that have that power to impact healthcare M&A and deal activity. With substantial economic and regulatory pressures, healthcare M&A activity in October declined, but remained steady overall. According to data captured in the LevinPro HC database on November 3, preliminary numbers indicate that there was a 17% drop in deal volume from September (195 transactions) to October 2025 (162 transactions). It is worth noting that September 2025’s high deal activity is more of an outlier; October’s activity was more consistent with the... Read More »
Salt Dental Partners Announces 10th Acquisition of 2025
On October 29, SALT Dental Partners announced that it expanded its New Jersey presence with the acquisition of Brick Pediatric Dentistry and Orthodontic. The financial terms of the transaction were not disclosed. Based in Brick, New Jersey, Brick Pediatric Dentistry and Orthodontic has two physicians on staff: Dr. Dawn Chillemi and Dr. Seymour Semah. Headquartered in Phoenix, Arizona, SALT Dental Partners is a dental partnership organization focused on specialty pediatric dentistry and orthodontics with more than 90 locations across 13 states throughout the country. SALT is a portfolio company of Latticework Capital Partners, a Dallas, Texas-based private equity firm. ... Read More »
RC Capital Partners With The Blanchard Institute of North Carolina
RC Capital announced on October 30 a new platform investment in The Blanchard Institute for an undisclosed price. The Blanchard Institute is a North Carolina–based provider of intensive outpatient and partial hospitalization behavioral health services. The company offers a comprehensive continuum of mental health and substance use services. Founded in 1994, RC Capital is a healthcare-focused growth equity firm based in Cincinnati, Ohio. The firm seeks to invest in commercial-stage medical technology companies operating in the healthcare services, medical devices and healthcare information technology sectors. “The growth investment in The Blanchard Institute underscores RC Capital’s... Read More »
Welltower Sells Outpatient Portfolio to Remedy Medical Properties & Kayne Anderson
Welltower announced on October 28 that it was divesting a medical outpatient building (MOB) portfolio to Remedy Medical Properties and Kayne Anderson Real Estate. The transaction will total $7.2 billion and will be completed in tranches through mid-2026, with the first tranche selling for $2 billion. The portfolio comprises approximately 18 million square feet across 296 properties in 34 states. The portfolio was 94% occupied at the time of the acquisition announcement. Remedy Medical Properties is a full-service healthcare real estate company and the largest private owner of healthcare properties in the country, with more than 33 million square feet and 25 offices spanning 44... Read More »
GSK Acquires Syndivia’s Preclinical Antibody Drug Conjugate for More than $357 Million
GSK Plc announced on October 29 that it acquired Syndivia’s preclinical antibody-drug conjugate (ADC). Syndivia’s preclinical ADC is in development for the treatment of prostate cancer. Syndivia developed the prostate cancer drug hopeful using its GeminiMab conjugation technology, which the biotech claims can create a unique drug-to-antibody ratio hinge region site-specific ADC. Syndivia is a French biotechnology company focused on the design and development of ADCs. Its proprietary technology enables the creation of next-generation ADCs with optimized therapeutic profiles, aiming to expand treatment options for patients with cancer. GSK, formerly... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
